Consolidative 32P after second-look laparotomy for ovarian carcinoma.
We report our experience with consolidative 32P after second-look laparotomy. Forty-three patients received consolidative 32P after platinum-based chemotherapy and a negative (39 patients, 91%) or positive (4 patients) second-look laparotomy. Thirty-one patients (72%) initially had stage III (30 patients) or stage IV (1 patient) disease; 28 patients (65%) had grade 3 tumors. Patients had follow-up from 3.5 to 14.9 years (median, 7.7 years); no patient was lost to follow-up. The 5-year rates of control of disease within the abdomen (local control) for the overall group and the subset of patients with stage II-IV disease and a negative second-look laparotomy were 65% and 69%, respectively. The corresponding 5-year survival rates were 78 and 81%, respectively. Multivariate analyses revealed that tumor found at second-look laparotomy significantly influenced the likelihood of local control and cause-specific survival. Acute side effects included cellulitis (1 patient) and ileus (3 patients). Two patients (5%) experienced severe late complications; both experienced small bowel obstruction that necessitated surgical intervention. Consolidative 32P appears to reduce the risk of recurrence and improve survival after negative second-look laparotomy. The risk of significant complications is low.
Condra
K S
KS
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville 32610-0385, USA.
Mendenhall
W M
WM
Morgan
L S
LS
Marcus
R B
RB
D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007813:Laparotomy; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000517:prevention & control / Q000532:radiotherapy* / Q000601:surgery*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D012008:Recurrence; D012086:Reoperation
D000970:Antineoplastic Agents; D010761:Phosphorus Radioisotopes